Key result
Aggressive treatment of LDL-cholesterol in patients undergoing coronary artery bypass grafting is evaluated in a recent trial update of the IMPROVE-IT subgroup analysis.
Why the study?
Does aggressive treatment of LDL-cholesterol improve outcomes in patients undergoing CABG?
Does aggressive treatment of LDL-cholesterol improve outcomes in patients undergoing CABG?
This editorial comments on a subgroup analysis of the IMPROVE-IT trial regarding aggressive LDL-cholesterol treatment in patients undergoing CABG.
A new subgroup analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) has been published.[1] In this Trial Update we briefly comment on this recent public...
No takes yet. Share an insight, caveat, or question.
Mikhailidis et al. (2016) studied this question. Aggressive treatment of LDL-cholesterol in patients undergoing coronary artery bypass grafting is evaluated in a recent trial update of the IMPROVE-IT subgroup analysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: